Double-edged sword of antipsychotic therapy: Navigating the intersection of psychiatric recovery, endoplasmic reticulum stress, and cardiovascular survival

Abstract

Individuals diagnosed with schizophrenia have been shown to have a significantly different lifespan, often dying 15 years to 20 years earlier than the general population. This excess mortality is primarily attributable to atherosclerotic cardiovascular disease, rather than the psychiatric symptoms themselves. Second-generation antipsychotics represent the prevailing standard of treatment in modern medicine; however, their efficacy is accompanied by significant drawbacks. While these medications are imperative in the prevention of suicide and relapse, they can concomitantly induce metabolic dysfunction. A rigorous examination of the molecular underpinnings of the endoplasmic reticulum stress response is imperative to elucidate its role as a mediator of antipsychotic-induced insulin dysregulation. Additionally, we examine the “clinical paradox” that the pursuit of psychiatric stabilization through pharmacotherapy may inadvertently expedite cardiovascular aging. Moving forward, clinical models must shift from an emphasis on individual variable analyses (e.g., body mass index or positive/negative symptom scale scores) to an integrated framework. This framework should consider the control of psychiatric symptoms as a prerequisite for metabolic health. In order to address the disparity in survival rates within this vulnerable population, there is a necessity to evolve research methodologies in order to facilitate clinical evaluation of a trinity of pharmacology, psychopathology, and lifestyle.

Key Words: Schizophrenia; Antipsychotics; Obesity; Cardiovascular disease; Endoplasmic reticulum stress; Insulin resistance; Integrated care

Core Tip: Cardiovascular mortality in schizophrenia is a systemic failure that cannot be solved by psychiatric or medical intervention in isolation. Effective care requires managing the molecular risks of medication alongside the functional necessity of psychiatric stability to enable life-saving lifestyle changes. Clinicians must recognize that antipsychotics like olanzapine pose dual risks: Chronic insulin resistance and acute, ketosis-prone diabetic emergencies.

INTRODUCTION

The public health crisis that has simmered for decades, namely the widening disparity in mortality rates for schizophrenia, continues to this day[1-5]. Despite the evolution of psychiatric care, individuals with schizophrenia continue to experience a disproportionate burden of physical illness[6]. The findings from the Second Xiangya Hospital of Central South University cohort demonstrate that approximately one in five patients experienced a major adverse cardiovascular event over a ten-year period[7]. This underscores the notion that metabolic management is not a peripheral concern; rather, it is a matter of survival. The study’s calculation of “vascular age” is arguably its most salient metric. When a patient aged 42 exhibits the cardiovascular profile of a 54-year-old, it signifies an accelerated biological aging process. This phenomenon is not merely a result of “poor choices” by the patient; rather, it is an outcome of a complex interplay between genetic vulnerability, the biological impact of chronic psychosis, and the iatrogenic effects of the very treatments designed to help. Recent research has also examined the correlation between metabolic disorders and functional brain imaging in patients treated with different medications[8].

MOLECULAR MECHANISMS: THE ROLE OF ENDOPLASMIC RETICULUM STRESS

One of the most significant advances in recent years is the suggestion that the molecular mechanisms by which antipsychotic drugs cause metabolic disorders may be different from what was previously thought. Conventional wisdom has long posited that weight gain is a straightforward caloric imbalance, precipitated by heightened appetite[9-11]. However, the papers that have been provided on the endoplasmic reticulum stress (ERS) response offer a more nuanced molecular explanation for why atypical antipsychotics are so metabolically toxic[12,13]. To simplify this mechanism: The endoplasmic reticulum acts as a cellular “factory” responsible for the folding and maturation of proteins, such as proinsulin in pancreatic beta-cells. Atypical antipsychotics act as a stressor that disrupts this factory line, causing an accumulation of misfolded proteins - a state known as ERS[14]. When the endoplasmic reticulum is overwhelmed, the cell triggers the “unfolded protein response”. While initially a repair mechanism, chronic unfolded protein response activation in the face of continuous antipsychotic treatment leads to the degradation of insulin rather than its secretion, effectively “starving” the body of insulin despite high production efforts[13]. This cellular dysfunction creates a direct path from protein-folding failure to systemic insulin resistance and beta-cell exhaustion. The endoplasmic reticulum is responsible for the folding and maturation of proteins, including proinsulin in the pancreatic beta-cells. Atypical antipsychotics have been demonstrated to induce ERS, thereby disrupting this delicate folding process[12-15]. Under conditions where large amounts of insulin are synthesized, the “unfolded protein response” is initiated. While the initial activation of this pathway is protective, its chronic activation results in impaired insulin secretion. Misfolded proinsulin is subject to degradation rather than secretion, resulting in a precipitous decline in insulin availability[12,13].

This ERS-mediated metabolic “hit” is a model for understanding many second-generation antipsychotics, particularly clozapine and olanzapine, which share a similar tricyclic structural formula. While ERS represents a primary molecular driver, it should be noted that this mechanism coexists with other pathways, such as the direct antagonism of histamine H1 and 5-hydroxytryptamine receptor 2C receptors, which significantly increase appetite and caloric intake. These drugs present a dual-risk spectrum such as typical type 2 diabetes presentation and acute ketosis-prone diabetes. A gradual progression driven by H1 and 5-hydroxytryptamine receptor 2C receptor antagonism, leading to weight gain and systemic insulin resistance. A rapid, direct insult to beta-cell function that can precipitate diabetic ketoacidosis even in non-obese patients without a family history of diabetes (Figure 1)[15]. Prolonged ERS has been demonstrated to result in the death of insulin-producing cells, thereby elucidating the high incidence of diabetes (18.4%) observed in the cohort[12,13]. Furthermore, ERS signals have been shown to interfere with insulin receptors in adipose and muscular tissue, thereby further exacerbating the metabolic syndrome. This molecular framework suggests that even before a patient shows visible weight gain, their cellular machinery is already being compromised. This underscores the necessity for a transition toward biochemical monitoring that occurs prior to anthropometric changes.

Figure 1 Molecular mechanisms of metabolic disorders caused by antipsychotics. Atypical antipsychotics carry the risk of inducing both insulin secretion dysfunction due to endoplasmic reticulum response stress and insulin resistance due to histamine H1 receptor and serotonin 5-hydroxytryptamine receptor 2C receptor inhibition. ERS: Endoplasmic reticulum stress; ER: Endoplasmic reticulum; 5-HT2C: 5-hydroxytryptamine receptor 2C.

PARADOX OF ANTIPSYCHOTIC TREATMENT

Studies using the advanced statistical tool QRISK3 algorithm have accurately identified “severe mental illness” and “antipsychotic drug use” as clinically important cardiovascular risk factors that require the same level of attention as established risk factors such as smoking and hypertension[7,16].

Nevertheless, a salient concern in numerous cohort studies pertains to the exclusion of psychiatric symptom severity as a dynamic moderator of metabolic health. Long et al[7] observed that patients with obesity exhibited lower Positive and Negative Syndrome Scale scores, which is indicative of more effectively managed symptoms. This finding is of critical importance, as it suggests that patients who are “successfully” treated for their psychosis are the ones most at risk of dying from a heart attack. This trend is supported by findings in the CATIE trial and subsequent meta-analyses[17], which suggest that the superior clinical efficacy of agents like clozapine and olanzapine is frequently tethered to the most severe metabolic profiles, thereby creating a direct, paradoxical link between psychiatric symptom control and cardiovascular risk. This ERS-mediated metabolic “hit” is a model for understanding many second-generation antipsychotics, particularly clozapine and olanzapine, which share a similar tricyclic structural formula. This phenomenon, known as the “treatment paradox”, presents a significant challenge for clinicians in their daily practice. When considering the metabolic risk alone, one might be tempted to reduce doses or switch to low-risk agents such as aripiprazole or ziprasidone[18,19]. However, in cases of refractory schizophrenia, these shifts frequently culminate in a resurgence of positive symptoms. It is improbable that a patient who has relapsed will adhere to a diet that promotes cardiovascular health, participate in metabolic screenings, or engage in the physical activity necessary to manage their body mass index[20-22]. Therefore, we must prioritize psychiatric stability as the foundational prerequisite for physical health management, rather than viewing them as competing interests[22-24].

NECESSITY OF INTEGRATED ANALYSIS

It is our contention that an approach that focuses on each factor - medication, lifestyle, or symptoms - in isolation will never allow for appropriate intervention. Recent evidence suggests a close relationship between psychiatric symptoms, metabolic disorders, and lifestyle habits, both in terms of positive and negative correlations, in individuals diagnosed with schizophrenia[25,26]. The molecular burden of insulin resistance (driven by ERS) directly connects to the need for integrated care; metabolic dysfunction increases systemic inflammation, which can further exacerbate psychiatric symptoms, creating a vicious cycle[15].

Uncontrolled psychiatric symptoms have been demonstrated to lead to social drift and isolation, poor nutrition, and high smoking rates[27]. Antipsychotic medications have been demonstrated to effectively manage symptoms; however, they have also been associated with weight gain and the development of ERS. Obesity and diabetes have been demonstrated to increase systemic inflammation, which may further exacerbate psychiatric symptoms and cognitive decline in individuals diagnosed with schizophrenia[28-30]. To address this issue, there is a need for research methodologies that can evaluate these factors in a simultaneous manner. For instance, there is a need for studies that measure whether the cardiovascular benefit of a “metabolically neutral” drug is offset by the cardiovascular cost of the increased smoking and stress that occur during a psychiatric relapse[31,32]. It is important to organize the factors that currently influence the mortality rate of schizophrenia patients, and next, we will organize them in relation to antipsychotic medications.

ANTIPSYCHOTIC MEDICATIONS AND CARDIOVASCULAR RISK

Individuals with schizophrenia face a stark reality regarding their mortality. Decades of research have consistently demonstrated that this population has a life expectancy 15 to 20 years shorter than that of the general population[1,33-34]. Alarmingly, recent studies suggest that this “longevity gap” may actually be widening rather than closing[1]. Despite these challenges, the leading contributor to the mortality gap remains cardiovascular-related death[35]. This has led to intense scrutiny of antipsychotic medications, which are known to influence metabolic pathways.

The relationship between antipsychotics and cardiovascular events is often described as a “double-edged sword”. On one hand, these drugs - particularly second-generation antipsychotics - are associated with weight gain, dyslipidemia, and insulin resistance, all of which are precursors to ischemic heart disease[36,37]. A systematic review found that heart disease and cardiovascular disease rank highest among cause-specific mortality for those on these medications, at a rate of 5.6 per 1000 person-years[38]. However, the assumption that the medications themselves are the primary drivers of increased mortality is not supported by long-term data.

Reduced all-cause mortality

Multiple large-scale meta-analyses and cohort studies have shown that the use of antipsychotics is actually associated with a lower risk of death compared to non-use[34,37,38]. One study reported that the risk of all-cause mortality was nearly halved (adjusted hazard ratio = 0.48) during periods of antipsychotic use compared to non-use[38].

Cardiovascular protection

Surprisingly, long-term antipsychotic use is associated with decreased cardiovascular mortality[38-41]. In a 20-year follow-up of over 62000 patients, the hazard ratio for cardiovascular death was 0.62 for those using antipsychotics vs those who were not[38].

No increase in severe morbidity

Within-individual analyses indicate that the use of antipsychotics does not increase the risk of hospitalization due to physical health problems or cardiovascular issues when compared to periods when the same individual is not taking the medication[42-45].

This suggests that while the side effects are real, the benefit of stabilizing psychiatric symptoms - which leads to better self-care, reduced stress, and lower suicide rates - outweighs the metabolic risks.

CLOZAPINE: HIGH RISK, HIGHER REWARD?

Clozapine occupies a unique position in psychiatry. It is the “gold standard” for treatment-resistant schizophrenia and is the only Food and Drug Administration-approved medication for reducing suicidal behavior in these patients[46,47]. However, it is also the medication most likely to cause severe metabolic disorders and other life-threatening side effects, including agranulocytosis, myocarditis, and seizures[48-53]. Despite this “shadow” of adverse effects, clozapine demonstrates a “light” in terms of survival.

Superior longevity

Continuous treatment with clozapine is associated with a significantly lower long-term all-cause mortality rate compared to other antipsychotics[35,54,55].

The 20-year outcome

In long-term Finnish cohorts, the cumulative mortality rate over 20 years was 46.2% for those not using antipsychotics, 25.7% for those using any antipsychotic, and only 15.6% for those specifically on clozapine[38].

Suicide prevention

Clozapine is remarkably effective at reducing suicide mortality, with one study showing a hazard ratio of 0.21 compared to non-use[38,56,57]. Interestingly, the risk of suicide appears to increase significantly immediately following clozapine cessation, suggesting that the period after stopping the drug is particularly high-risk[58].

The “clozapine paradox” exists because its superior efficacy in controlling symptoms and preventing relapse provides a protective effect that far exceeds the dangers posed by its side-effect profile[34,35]. Why does clozapine, despite its metabolic baggage, extend life so effectively? Beyond its psychiatric efficacy, researchers are investigating biological pathways that might slow the aging process.

Epigenetic age and longevity pathways

Recent studies have analyzed the “DNA methylome” to determine the difference between a person’s chronological age and their epigenetic age. In patients treated with clozapine, the “delta age” (the difference between biological and actual age) was found to be lower on average compared to drug-naïve patients[54,59]. This suggests that clozapine may actually slow biological aging at a cellular level. Furthermore, clozapine treatment appears to promote the hypomethylation of longevity-regulating pathway genes, particularly those involving AMP-activated protein kinase and insulin signaling[54]. These molecular changes might provide a degree of systemic protection that offsets the drug’s metabolic risks.

Neuroprotection and neuroplasticity

There is a growing field of research suggesting that clozapine may have broader beneficial effects, including promoting neuroprotection and neurotrophism[46]. By fostering neuroplasticity and regenerative effects in the brain, clozapine may help preserve functional independence and cognitive health, which are critical components of long-term survival in geriatric populations[46,60].

CLINICAL DILEMMAS

The evidence clearly indicates that the primary risk to patients with schizophrenia is not the treatment, but the absence of treatment[37,38]. However, the metabolic and cardiovascular risks associated with antipsychotics - especially clozapine - cannot be ignored. While it has been asserted that patients treated with clozapine have a longer lifespan, this is only true within the schizophrenic population and not in comparison to the general population. To bridge the longevity gap, a multi-faceted approach is required.

Integrated care

Co-locating physical and mental health services can help address the cardiovascular needs of patients in a specialized environment[34].

Proactive management of adverse events

Effective management of clozapine’s side effects requires individualized, shared-decision strategies and inter-disciplinary solutions[36]. Clinicians must be educated on early identification and management of risks like myocarditis and agranulocytosis[36,46].

Early intervention

Addressing mortality risks should begin as early as possible in the course of treatment through specialized early intervention services[34].

Antipsychotic medications, and clozapine in particular, represent a vital intervention for schizophrenia. While they carry significant risks for cardiovascular and metabolic events, the data overwhelmingly shows that they are life-saving tools. By controlling psychiatric symptoms, reducing suicide risk, and potentially modulating biological aging pathways, these medications provide a path toward closing the 15-20 years longevity gap. Data highlights the fundamental clinical challenge: While the metabolic side effects of clozapine and other second-generation antipsychotics are significant, the protective effect they provide against all-cause mortality - including cardiovascular and suicide-related deaths - is substantial (Table 1)[38]. The significantly lower cumulative mortality rate for clozapine users over two decades suggests that its efficacy in psychiatric stabilization is a primary driver of long-term survival. The challenge for modern medicine is not to avoid these drugs, but to master the “double-edged sword” through integrated, vigilant, and person-centered care.

Table 1 Relationship between antipsychotic drug prescriptions and mortality rates.

Study metric	No antipsychotic use	Any antipsychotics	Clozapine
All-cause mortality (aHR)	1.00 (reference)	0.48	0.39
Cardiovascular mortality (aHR)	1.00 (reference)	0.62	0.55
Suicide mortality (aHR)	1.00 (reference)	0.52	0.21
20-year cumulative mortality (%)	46.2	25.7	15.6

Adjusted hazard ratios are based on the Finnish nationwide cohort[38]. A lower ratio indicates a higher protective effect compared to non-use. aHR: Adjusted hazard ratios.

FUTURE CLINICAL APPROACHES: FROM SCREENING TO STRATEGY

In summary, the aforementioned discourse posits that contemporary “guideline-compliant” care, which frequently concludes with the assessment of body mass index and blood glucose levels, is inadequate. We hereby propose a more aggressive, integrated strategy (Table 2). Given the immediate onset of ERS and weight gain upon drug initiation, the prescription of ERS-mitigating agents or glucagon-like peptide-1 agonists in conjunction with antipsychotics from the first day of treatment (early “metabolic protective” co-prescription) is a plausible approach. However, the implementation of such early combination therapy faces significant practical hurdles. These include the high cost of glucagon-like peptide-1 agonists, varying medical insurance coverage, and the potential for increased side-effect burdens affecting patient tolerance. Furthermore, while the biological rationale is strong, there is currently a lack of evidence from large-scale, long-term randomized controlled trials specifically testing “first-day” co-prescription. Future research must prioritize these randomized controlled trials and cost-effectiveness analyses to transform this conceptual strategy into a standard of care. This finding is of critical importance, as it suggests that patients who are “successfully” treated for their psychosis are the ones most at risk of dying from a heart attack. The “single-center” success of the Second Xiangya Hospital of Central South University suggests that physical health must be managed within the psychiatric setting. Individuals diagnosed with schizophrenia frequently encounter challenges related to stigma and accessibility in primary healthcare settings. The integration of laboratory and cardiological services within psychiatric clinics is imperative to address these concerns (psychiatric-cardiometabolic clinics). For patients prescribed clozapine, the prevailing standard of care for cases that are refractory but present elevated metabolic risk, the emphasis should shift from a mere “switching” of the pharmaceutical agent to an assertive, multifaceted approach to metabolic defense. The documented evidence indicates that failure to treat refractory schizophrenia can result in a significantly diminished lifespan. Consequently, it is imperative to acknowledge the potential risks associated with medication, while concurrently employing strategies such as secondary pharmacology and structured lifestyle interventions to mitigate these risks (reframing refractory care)[33]. This includes addressing non-pharmacological gaps by integrating “exercise as medicine” programs directly into psychiatric clinics, ensuring that lifestyle interventions are feasible for those with cognitive or social barriers.

Table 2 Clinical evaluation checklist: Integrated metabolic-psychiatric care.

Domain	Assessment item	Status/metric	Clinical action if red flag
Psychiatric stability	PANSS score/clinical impression	Stable vs fluctuating	Do not switch meds if stable; prioritize adjuncts over switching
Psychiatric stability	Suicide risk assessment	Low vs high	If high, prioritize clozapine/Lithium regardless of metabolic risk
Metabolic markers	HbA1c/fasting glucose	< 5.7% (target)	If elevated, consider metformin or GLP-1 RA early
Metabolic markers	Triglyceride/HDL ratio	Target < 3.0	Consider statins or ERS-mitigating nutraceuticals
Anthropometrics	BMI and waist circumference	BMI < 25/waist < 102 cm (male)	7% weight gain from baseline triggers intervention
Lifestyle habits	Smoking status	Yes/no	Provide nicotine replacement or varenicline immediately
Lifestyle habits	Physical activity (steps/day)	Target > 7000	Referral to “exercise as medicine” psychiatric programs
Pharmacology	Medication load	Monotherapy vs polypharmacy	Reduce polypharmacy; calculate chlorpromazine equivalents 600 mg or less

This checklist is designed for clinicians to use at 3-month intervals to ensure that neither metabolic health nor psychiatric stability is being sacrificed. PANSS: Positive and Negative Syndrome Scale; HbA1c: Glycated hemoglobin; HDL: High-density lipoprotein; BIM: Body mass index; GLP-1 RA: Glucagon-like peptide 1 receptor agonist; ERS: Endoplasmic reticulum stress.

CONCLUSION

The pharmacotherapy of schizophrenia represents one of the most intricate risk-benefit assessments in contemporary medicine. Antipsychotic medications are imperative in the management of psychotic symptoms and the prevention of relapse; nevertheless, these medications are frequently met with apprehension due to their association with metabolic and cardiovascular adverse effects. Contrary to popular belief, pharmaceuticals that are commonly prescribed to treat physical ailments have been shown to have significant benefits in prolonging patients’ lives. In contemplating future prospects, it is imperative to avert a potential dearth in treatment for underlying psychosis, precipitated by an overcautious approach to the adverse effects of antipsychotic medications. The future direction of research in this field will likely center on recognizing that the “mind” and “body” in schizophrenia are interconnected through molecular pathways such as ERS and behavioral pathways such as lifestyle habits influenced by symptoms. In order to extend the lifespan of this vulnerable population, it is essential to emphasize the introduction of research and clinical methods that ensure a balanced approach that comprehensively evaluates patients, considers the need for symptom management, and recognizes the molecular basis of metabolic risks. It is imperative to shift our perspective regarding the notion that mental well-being and cardiovascular health are inherently incompatible.